17081 Background: The clinical significance of three-dimensional stereotactic radiotherapy (SRT) for primary lung cancer has been demonstrated by a few studies. This study was performed to evaluate the clinical outcomes of SRT for treating metastatic lung cancer using a stereotactic body frame. Methods: Of the forty-one patients who were treated between October 1998 and December 2004, thirty-four patients were evaluated in this study. All patients had less than two lung solitary metastases without any other metastases and primary recurrence. Fifteen patients were metastasis from primary lung cancer. The other 9 had metastasis from colo-rectal cancer, 5 from head and neck cancer, 3 from renal cancer, 1 from breast cancer, 1 from osteosarcoma of femur. All tumor size was less than 4 cm in diameter. Three-dimensional treatment planning using 5 to 8 non-coplanar beams was performed to maintain the target dose homogeneity and to decrease the irradiated lung volume >20 Gy. All patients were irradiated using a stereotactic body frame and 18 received 4 single 12 Gy, 16 recieved 5 single 12Gy of radiation at the isocenter over a period of 4–18 (median = 12) days. Results: Four patients (4/34%) completely disappeared after treatment (CR) and nine (9/34%) decreased in size by 30% or more (PR), eighteen had no tumor progression in clinically (SD). Three had progress disease (PD). Twenty-eight (82%) of 34 tumors were locally controlled during the follow-up period. Local recurrences and new metastase occurred in one and six of lung cancer patients, one and three of colo-rectal cancer patients, respectively. For recurrent primary lung cancer, the overall survival rates after one and three years were 100 and 63%, respectively, while for secondary lung cancer from colorectal cancer, the overall survival rates were 100 and 71%, respectively. During the follow-up of 10.5–80.6 (median = 27.3) months, no pulmonary complications greater than an CTC-AE V3.0 criteria of grade 4 were noted. Conclusions: Sterotactic radiotherapy using a stereotactic body frame was useful for the treatment of metastatic lung tumors. No significant financial relationships to disclose.
Prognostic Value of Intraoperative Pleural Lavage Cytology as an Independent Prognostic Factor in Non-Small Cell Lung Cancer: A Retrospective Study